Recursion Pharmaceuticals, Inc. - Class A Common Stock - Çeyreklik Finansal İstatistikler (NASDAQ:RXRX)

Financials

İşletme faaliyetlerinden elde edilen nakit -115.43 M-131.96 M-76.42 M-117.36 M-46.07 M-81.1 M -320.95 M Yatırım faaliyetlerinden elde edilen nakit 275.46 M-7.27 M-5.81 M-2.55 M-1.24 M-338 K -9.94 M Finansman faaliyetlerinden elde edilen nakit 10.64 M40.53 M97.66 M251.34 M132.01 M-3.47 M 477.54 M Serbest nakit akışı -115.43 M-131.96 M-79.57 M-117.6 M-47.32 M-81.44 M -325.93 M

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals is a clinical-stage biotechnology company that focuses on mapping and decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering. The company is based in Salt Lake City, Utah. It was founded by Chris Gibson, Dean Li and Blake Borgeson.

RXRX

Financials

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Haberler

Two Months. $10 Million. A Sputnik Moment for AI.

Recursion Pharmaceuticals hissesi 2,79 dolarla dip yaptı

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Recursion 1Ç 2026: Gelir zorluklarına rağmen yapay zeka ilerliyor

Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine (TEM)

RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y

Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates

AI Revolutionizing Biopharma: Faster, Better, Cheaper (NYSEARCA:XLV)

Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts

LLY Stock Jumps After Q1 Earnings Beat, 2026 Guidance Raised

Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know

Recursion: No Longer An AI 'Pet Science Project,' But Still A 'Sell' (NASDAQ:RXRX)